ELAST-AGE

advertisement
ELASTAGE – FP6 – Final Activity Report
Project n° 018960
Project Acronym:
Project title:
ELAST-AGE
Targeting the elastic tissues ageing to
improve the quality of ageing
Instrument: Specific targeted Research or innovation project
Thematic priority: Life sciences, genomics and biotechnology for health
Publishable Final activity report
2006 - 2008
Project co-funded by the European Commission within the Six framework programme (2002-2006)
Dissemination Level
PU
PP
RE
CO
Public
Restricted to other programme participants (including Commission services)
Restriction to group specified by the consortium (including the Commission services)
Confidential, only for members of the consortium (including the Commission services)
1
ELASTAGE – FP6 – Final Activity Report
TOWARDS THE MAINTENANCE OF TISSUE ELASTICITY
FOR HEALTHY AGEING
GENERAL PRESENTATION:
The complex features of ageing are far from being understood. Ageing is accompanied by
several "age-associated' diseases, most of them involving a tissue disorganization of organs
and their tissues environment. One of the most apparent manifestations of ageing is the loss of
tissue elasticity, with its obvious consequences for skin elasticity, and though more difficult
to appreciate, for breathing or for the regulation of pulse pressure and, consequently, cardiac
function.
Elastic fibers synthesis occurs during development and early adult growth, but is scarce in
adults where it is often associated to the formation of non functional elastic fibres and
pathology. In human, age-related dysfunction of elastic tissue is associated with
arteriosclerosis, aneurysms, hypertension, varicous veins, skin wrinkles, hernia, lung
emphysema, degeneration of inter-vertebral disc, ligaments or tendons, macula degeneration
or glaucoma. Furthermore, the lack of elastic fibers formation explains the poor skin repair for
severe burns or hernias; while the pathologic accumulation of amyloid-like elastin deposit is a
classical manifestation of solar elastosis. Therefore, ageing of elastic tissues is related to
general ageing and is considered as a factor amplifying the ageing processes.
The mechanisms that govern correct elastogenesis are still unknown. However, the
previous decade of fundamental research has largely contributed to a better understanding of
the composition and assembly of elastic fibres. Besides the determination of about 30
components that built up the elastic fibres, several genes defective in inherited disorders of the
elastic fibres have been identified, such as for the Marfan Syndrome, Cutis laxa,
Pseudoxanthoma elasticum, or more recently the Exfoliation Glaucoma. This has leaded, very
recently, to propose a therapy for children displaying the Marfan syndrome through the use of
anti-hypertension drugs that target some side effects of the imperfect elastogenesis associated
to this syndrome.
In this context of very active and exciting research, several European teams have
coordinated their efforts to find "positive modulators" for elastic tissue ageing. The goal of
their project is to target the ageing of elastic tissue to cope with ageing, or at least some
manifestations of ageing. The ELASTAGE project has been supported by the European
Community through the FP6 programs (2006 – 2008). The project brings together 12
participants with complementary expertise from 6 different countries, including basic
scientists, clinicians, one large enterprise and two small enterprises. Ethical, gender and
standardisation aspects are also included. Collaborations throughout Europe or worldwide
have expanded this network, while participants of the consortium are the main organizers of
the biannual Elastin European Conference.
The originality of ELASTAGE lies in the coordination of strategies for (i) the development
of molecules that could protect or delay degradation of elastic fibres or aged-dependent
modifications or (ii) for the discovery of active compounds that could induce functional
2
ELASTAGE – FP6 – Final Activity Report
elastic fiber synthesis in adults. The expected impacts should be a breakthrough on skin and
vessel ageing treatments with a special interest with the improvement of chronic vein
insufficiency and, longer term, other disorders of joints, arteries and macula and the
improvement of healing.
MAIN RESULTS:
The research made by the different partners was focused on understanding the elastic fibres
life, from their formation to degradation, in vitro, ex vitro and in vivo. ELASTAGE was
subdivided in 5 scientific workpackages (+ two WP on dissemination and management),
which merged during the program.
1 – Characterizing the assembly of elastic fibres at the molecular level (WP2, WP4):
One objective realized by the consortium was to define how elastic fibres assemble and the
main sites of elastic fibres degradation. This is particularly helpful for identifying protective
molecules that could limit the degradation of elastic fibers. These molecules are chemically
close to the heparin structure or from extracellular matrix proteins.
The way the elastic fibers assemble is still far to be understood. Therefore, efforts are still
needed to further describe this assembly, in order to know how to favour it.
 By in vitro expressing different components of the elastic fibres, the consortium
gained many new insights into the elastic fibre ‘interactome’. Studies were made using
portions or complete part of the two main structural proteins of the elastic fibres, elastin
and fibrillin 1. Interactions studies were also made with essential proteins partners
(fibulins-4 and -5, tropoelastin, heparan sulfate, fibrillin-1, lysyl oxidases…). This large
study has allowed building a 3D map of potential elastic fibre interactions that will be very
useful for establishing the components favouring elastic fiber formation in vitro
(Deliverable D2.3).
 A map of the elastin sites the most susceptible to elastase degradation was established.
This work will give the basis to design peptide – mimetics that might protect elastic fibers.
Heparin and heparan sulphate derivatives were developed for such purpose. At first,
collagenase inhibition activities were found with various heparin fractions and synthetic
molecules. Further experiments should allow finding inhibitors of elastase (D2.2; D2.4).
This program has given further insights on the life of elastic tissues: the way they
assemble, the way they are degraded, the basis of there biomechanical properties. This
knowledge is still essential to appreciate the unique elastic properties of those fibers, and
there evolution throughout the life.
2 – Building up elastic fibers at the cell level (WP2, WP4):
Beside the exact composition of elastic fibres, it is yet unknown how the cells are working
to establish elastic fibres, with their peculiar tissue organization.
 The “elastic fibre interactome” study has been extended at the cell levels. This
complex study confirmed known interactions, and identified or validated several novel
interactions with growth factors and cell receptors, and demonstrated higher-order elastic
3
ELASTAGE – FP6 – Final Activity Report
fibre interaction networks linked to fibronectin and heparan sulphate proteoglycan,
respectively (D2.3).
 One selected fraction of natural heparan sulphate significantly increased the
expression of elastin in fibroblasts (D2.2, D4.1).
 Elastin peptides themselves regulate the cell phenotype. The consortium showed that
elastin peptides are able to counterbalance ceramide-induced apoptosis in human skin
fibroblasts, through the anti-apoptotic Akt kinase pathway (D4.1, D4.2).
This program participates to the global progression of knowledge about the
formation by cells of elastic fibres, indispensable to therapeutically target them as a
whole, or as unique components.
3- Linking aging and aging of elastic tissues in cell culture (WP2 – WP5)
In order to link global aging and aging of elastic fibres, different experiments have been
conducted in cell culture with cells from young and old donors. Healthy and pathological
biological samples were shared. They came from skin, most easily available, and from
varicose vein tissues. In this latter case, it is possible to get tissues and cells from the
environing “healthy” tissue (from vein and skin).
 A proteome analysis on fibroblasts highlighted proteins that change their expression
depending from the age of donors and/or from the in-vitro aging. The expression of known
senescence markers (beta-galactosidase, caveolin-1) and several other proteins (protein
disulfide isomerase, calreticulin …) was dependent of in-vitro aging, but not so much of
the age of donors. Elastin expression was not really affected, in contrast to fibulin 5. This
protein is particularly interesting for our studies as it connects elastic fibres to cells and
causes cutis laxa when mutated (D4.1).
 To introduce a functional genomic approach, the consortium designed a custom gene
expression microarray for the measurement of selected skin and blood vessel transcripts.
“Elastarray”, as we have named it, contains 91 probes for the measurement of transcripts
encoded by 45 genes. In addition, it contains control probes for data normalization and
verification of technical performance. Preliminary validation on fibroblasts from young
versus post-menopause women indicated satisfactory reproducibility for 55 genes, which
can now be further tested as markers of aging in our models (D3.3; D.4.1; D5.1; D5.5).
 The expression level profile of elastic fibres genes appears very low in adult vascular
smooth muscle cells established from varicose veins (D3.3).
In conclusion, this program highlighted markers of aging and aging of elastic tissues
in cell models. These markers will be useful for further research aiming to understand
what is missing in adult cells and tissues that is present in developing and young elastic
tissues. The DNA “Elastarray” should be available soon, once completely validated with
the different models used by the consortium.
4 – Improving tissue engineering (WP2 -WP5):
ELASTAGE has been also successful in proposing biomaterials that display some
biomechanical properties of elastic tissues: this is particularly important to design
cartilaginous, skin, vascular or cardiac valves grafts. These biomaterials have been proposed
4
ELASTAGE – FP6 – Final Activity Report
on the basis of some chemical and biological characteristics of elastic tissues that have been
carefully detailed by the consortium.
Several approaches were envisaged either to test elastic fibre molecules as scaffold or to
favour the formation of elastic fibres in tissue engineering protocols.
 From the interactome study, it was inferred and demonstrated that fragments of
fibrillin-1 and fibronectin both supported strong endothelial cell adhesion and spreading.
An improved 3D fibrin gel model also allowed the abundant and ordered fibrillin-1
depositions, with enhanced cross-linked elastin expression and deposition (D2.3).
 From the molecular study of elastin sequences, elastin-derived peptides were designed
and tested as potential scaffold for tissue engineering d2.5).
 From the detailed analysis of glycosaminoglycans, heparan and heparan like
derivatives were identified as compounds able of influencing elastogenesis and elastic
fibers protection. Samples of horse tendon collagen, which will be further enriched with
those elements to favour elastogenesis, were prepared as sponge tube for the preparation of
vascular prosthesis. Such collagen scaffold is currently tested with human vascular smooth
muscle cells under defined pulsatile sheer stress conditions in a glass bioreactor. These
scaffold will be further enriched with heparan sulphate and/or heparan like sulphate to
favour elastogenesis (D2.4; D2.5).
 A skin equivalent was used that allows the formation of true elastic fibers in vitro.
This model was based on the culture of fibroblasts on a glycoaminoglycan – collagen –
chitosan scaffold, on which keratinocytes were further seeded. A model of cutis laxa skin
equivalent was further set up on this basis. It was developed using fibroblasts from a young
cutis laxa donor harbouring a fibulin 5 mutation. This model confirmed the global
weakness of the whole deposition of extracellular matrix, but also highlighted the
unexpected poor formation of the basement membrane between the dermis and epidermis
(D5.2; D5.3).
These data highlighted the complexity of elastic fibres formation in tissue culture
models. Different ways have been proposed that positively affect the engineering of
elastic tissues. This knowledge and practical propositions will be spread to the
international community, in order to improve the biomechanical properties of
biomaterials. One activated collagen scaffold has been patented and available soon on
the market, the “activated” form enriched with heparansulphate is going to be ready
soon. Elastin derived sequences should be further investigated for their potential
applications in tissue engineering.
5 – Testing models of vascular ageing: from rodents to human (WP1, WP3)
One of the main difficulties when dealing with the understanding of true aging
mechanisms is the choice of appropriate models. Except the skin, human tissue samples from
healthy donors are not easily obtainable, except surgical residues from coronary bypass
grafting or varicous surgery for instances.
The consortium has therefore explored three rodent models, which might be used to test
the effectiveness of “positive modulators” on age-related cardio-vascular disorders. These
rodent models were chosen because they display characteristics of accelerated ageing and
exhibit an aortic elastin deficit (D1.1):
5
ELASTAGE – FP6 – Final Activity Report

A senescent accelerated mouse strain (SAM8) was chosen for its inherited short
life span (the so-called “senescence accelerated mouse”). It appeared characterized by an
enhanced reactivity to adrenergic vasoconstrictors, size variations of aortas, arteries and
veins, variations of their vessel wall (abdominal and iliac arteries and femoral vein), a
global decrease of the desmosine / hydroxyproline ratio (representative of the elastin /
collagen ratio) and more post-translational modifications of elastin related to age
(Advanced Glycation End).
 The elastin (haplo-) insufficiency (Eln +/-) mouse model has been obtained by
elimination of one allele of the elastin gene. It does not undergo any age-related wall
thickening but display a decreased distensibility of their aortas, resembling premature
ageing. Preliminary experiments suggest a shorter life span.
 The Brown Norway rats are more representative of arterial pathologies related to
ageing (such as aneurysm susceptibility).
 The human cardiovascular system was studied on aortic samples from patients
undergoing coronary bypass grafting. Near-infrared femtosecond multiphoton laser
scanning microscopy (NIR-LSM) highlighted the loss of elastic fibres as a function of age.
This was correlated to a constant decrease of elastin mRNA, estimated of approximately 50
% every 10 years of ageing (Gender and Diabetes had no impact).
In conclusion, it is hard to define one unique model of aging. They all display specific
characteristics of aging, i.e., the loss of elastic fibers. The investigation of tissue samples
using NIR-LSM technology will be of great interest for the community. These tools are
now ready to be shared. They would be very interesting to test substances that could
delay and treat some manifestations of aging.
6- Investigating potential treatments for vascular elastic fibers deficiencies (WP1,
WP3 – WP5)
Minoxidil, a potassium channel opener clinically used as anti-hypertension drug, has been
selected from previous studies as a potential candidate medicament to activate the formation
of elastic fibers of rodent aorta.
A dill extract has been selected from of a plant extract library by members of the
consortium. It was efficient to activate the formation of elastic fibers in human cells and
human skin equivalent.
 Minoxidil treatments were performed on old adult Brown Norway rats, during ten
weeks to 5 months. It was possible to increase the elastin content in the aorta of young
growing animals (elastin synthesis is still active) but no effect was observed on the adult
animals (elastin synthesis is very low). The effects might be explained by the increased
stability of mRNAs encoding other elastic fibre components (D1.2).
 Chronic treatment with minoxidil in aged Eln+/+ mice and its consequences on
cardiovascular function is still under way. However, some experiments already showed
that: 1) chronic minoxidil treatment modified the arterial mechanics and significantly
decreased the blood pressure in young 6 month-old Eln+/- mice (hypertensive), even long
after the end of the treatment, suggesting a definitive remodelling of the vessels, and 2)
age-related thickening of the aorta wall was reversed by minoxidil treatment in aged
Eln+/+ mice (D1.2).
6
ELASTAGE – FP6 – Final Activity Report
The dill extract was added to confluent smooth muscle cells isolated from the saphenous veins
from donors with Venous Insufficiency Chronic (VIC) syndrome. This dill extract induces an
increase of elastin in varicose veins from men, younger or older than 50 years old.
Surprisingly, it has no effect on women varicose veins, (D3.3; D5.5).
The use of Minoxidil might be interesting as a therapeutic approach against the
elastic fibres deficiency. Such treatment appeared more efficient on young organisms
and could be prioritised for helping the growth of children harbouring inherited
imperfect elastogenesis. As Minoxidil is already used in clinic, our results could be
translated for potential therapy of the Williams Syndrome patients, who exhibit an
inherited deficit of elastic fibres. Molecules with the same activity, but with fewer side
effects, should also be derived as cardiac hypertrophy can eventually be linked to the
stimulation by Minoxidil (the consortium showed that this can be suppressed by another
hypotensive drug, irbesartan).
The dill extract appears efficient on vascular cells from varicose veins. These veins
display a loss of elasticity due to a drop of smooth muscle cells (SMC) in the media, a
decrease in the elastin content and a reduction and fragmentation of fibres. Therefore,
the next step will be to understand how the dill extract works and if it can be used for
preventing the “leakage” of various elastic tissues in aging.
7 – Assaying therapeutic treatment against skin elastic fibres degeneracy (WP4 –
WP5)
The dill extract was efficient in activating the formation of elastic fibres in skin fibroblasts
and skin of post-menopause donors. In this latter case, dermatological trials concluded to a
decrease of the number and size of the wrinkles of the face and an improvement of elasticity
of the skin.
Oxidative stress appeared increased in fibroblasts from old donors. This indicates that
redox homeostasis is altered in dermal fibroblasts and represents the first sign of the aging
process. Therefore, antioxidants were tested on aging of elastic tissues.
Fast ageing human models were used: cutis laxa and pseudoxanthoma elasticum (PXE).
Cutis laxa is characterized by fragile elastic fibres, while PXE is representative of an
accelerated calcification of elastic fibres. Premium data highlighted in PXE the importance of
oxidative stress and altered vitamin-K recycling in controlling degeneration and calcification
of elastic fibers.
 Preliminary experiments using the DNA Elastarray dedicated to elastic tissue aging
highlighted several genes influenced by the dill extract, among them some main
components of elastic fibres (elastin, fibrillin 1, fibulin 4, the elastin binding protein…)
(D4.2; D51; D5.2).
 Active molecules of the dill extracts have been individualized and are currently under
investigation. One possible exciting explanation for the dill extract activity is that it can
directly induce the up-regulation of elastic fibres related genes at the promoter level by
modulating the epigenetic machinery being able to rescue silenced genes (D4.2; D5.4).

The dill extract was also tested upon fibroblasts from the cutis laxa donor harbouring
a fibulin 5 mutation. Preliminary data suggested a significant increase of elastic fibres
deposition, at least in vitro (D5.5).
7
ELASTAGE – FP6 – Final Activity Report
 Two antioxidants (vitamin E and Resveratrol) both lead to fall down the activity of
the reactive oxygen species. However, effect on elastin synthesis on the cell monolayer
was negligible (D4.1; D5.5).
In conclusion, the dill extract was efficient in reinducing elastogenesis on skin
fibroblasts from adult donors. Therefore, the dill extract has been launched on the
cosmetic market by one company of the consortium. It might also be relevant to
counterbalance the decrease of other elastic tissues during aging, through epigenetic
mechanisms. While antioxidant strategies could be helpful as complements to limit the
bad evolution of elastic tissue during ageing.
8 – Developing molecules able to interfere with the formation of elastin derived
amyloid fibers(WP2):
It is well known that the formation of abnormal elastic fibers is associated to pathology,
such as in solar elastosis and aging. An in vitro approach has been designed to define which
(and how) elastin fragments undergo amyloid aggregation (D2.1)..
 A complete picture at the molecular and supramolecular level of the amyloid-like
aggregates was obtained for elastin domains in the carboxy teminal region of elastin.
Several factors favoring the amyloid formation were defined (temperature, lipids, salts,
concentration).
 On this basis, some pentapeptides able to disfavor aggregation were designed mainly
on the basis of elastin sequences. These peptide molecules could represent lead compound
for the development of anti-amyloid agents active as inhibitors in elastin amyloid as well
as in A-amyloid formation.
In conclusion of this part, a new approach has been initiated to interfere with the
formation of elastin derived amyloid fibers; This finding should now be completed at the
cell and tissue levels, in appropriate models that need to be developed.
FINAL DISCUSSION:
In summary, ELASTAGE, granted by the European Community, has been successful in
bringing to life innovative markers, models, procedures and reagents that could be useful for
the maintenance of the elastic properties of the body while ageing or for bioengineering.
Several paths have been explored and many data have been collected, that will contribute to a
better understanding of elastic tissues, from their formation, in vitro and in vivo, to their
ageing. Some programs should be continued, either as singular research programs related to
elastic tissue, or as merged to other broader programs.
PUKH: ELASTAGE has been successful in disseminating European research on the
elastic tissue field at a high level. At the present time, 33 publications have been accepted
(about 10 more are anticipated), 3 exploitable products have been launched or patented for the
pharmaceutical and cosmetic markets, for translation to the well-being of the European
citizen.
8
ELASTAGE – FP6 – Final Activity Report
The comprehensive PUKD list at the date of submission (the 15th of February 2008) is
provided in annexe.
MILESTONES:
The milestones “Identification of cleavage sites on tropoelastin/fibrillin-1 in order to
design peptidomimetics as degradation preventing drugs” or the “Identification of heparansulphate (HS) and peptido-HS complex prototypes as degradation preventing agent” have
brought several improvements for the understanding of elastic fibers assembly and its
prevention against age – dependent evolution (degradation and amyloid formation).
The finding and validation of positive regulators of elastic fibres assembly also gave
exciting data. This corresponds to the milestones “Selection of compounds favouring elastic
fibre synthesis/assembly by A-vSMC and fibroblasts in 2D”, “Evaluation of positive
modulators on A-vSMC/fibroblasts in 3D (+ shear stress for A-vSMC)”, “Evaluation of
compounds for vessel-equivalent grafted animals”, “Identification of new
mechanisms/pathways of action”, “Identification by gene arrays and by proteome analysis the
presence of possible markers for elastin renewal and/or protection”. These ended up with the
validation of the dill extract, minoxidil, heparin / heparan sulphate derivatives and several
elastic fibres derived peptides (from elastin and fibrillin 1). These products are now ready to
best tested at a higher scale for pharmacological purposes.
Different technical protocols were improved for the vessel / skin equivalents, protein /
DNA biomarkers determination, clinical trials, resulting in a better knowledge: “Adjustment
for the aged skin-equivalent model to robotized methods”, “Improvement of tissue-equivalent
elastic properties”.
The introduction of models of fast aging of elastic tissues was very valuable for the
consortium: The comparison of aging and cutis laxa has allowed to highlight common
epigenetic mechanisms at work; Pseudoxanthum elasticum was characterized by a huge
increase of oxidative mechanisms, as in chronological aging; the elastin deficiency of ELN
+/- mice worsens pathological disorders associated to normal ageing, the use of cells from
human varicose veins has brought an interesting model. These data have highlighted common
mechanisms between aging and aging of elastic tissues, very useful for treating the disorders
associated to aging: “Introduction and testing the selected drugs on cells from "accelerated
elastic fibre ageing" disorders (cutis laxa, PXE, VIC)”; “Identification of common
mechanisms between accelerated ageing mice with elastic tissue component deficiencies” ;
“Determination of the effect of elastin ageing modulation on global ageing”.
9
ELASTAGE – FP6 – Final Activity Report
PERSPECTIVES:
Different specific programs should be completed, for final dissemination of ELASTAGE
data (publications, patents, market products, procedures). New programs should be opened,
to answer questions that have not been solved during ELASTAGE, or new questions that were
raised from data obtained during ELASTAGE.
Basic research specific to the elastic fibres field must be continued. ELASTAGE, which
follows another program more based on fundamental research (FP5 – TELASTAR – 2002 –
2004), has allowed the construction of a true and strong European community. Some
members of this consortium are now leading researchers in the field. They participate to
and/or organize the European and Gordon Elastic Fibers conferences, set in alternation each
two years. Therefore, this community will continue to work together to address the still not
fully unsolved question of how the fibres assemble at the molecular and tissue levels.
The formation of Amyloid aggregates from elastic fibres and the discovery of molecules
that could dissociate these aggregates are very exciting issues coming up from ELASTAGE.
Further investigations would require a better chemical understanding of their formation. It
would also require the development of cell and tissue models necessary to characterize the
biological conditions of their formation, to test their disappearance after potential treatment
and to define their pathological relevance. A specific dedicated program, between chemists,
biochemists, cell biologists and pathologists of the field would be appropriated.
Research on tissue engineering should be carried on and extended. ELASTAGE has
brought new exciting data in that field, which might really improve the procedures. This is of
particular importance as the properties of several reconstituted tissues are limited by the lack
of true elastic fibres neosynthesis: skin from burned patients, cardiac valves, arterial stents,
and ligaments, for instance. However, these programs should merge to other programs
dedicated to tissue engineering or introduce new concepts, such as orienting adult stem cells
towards elastogenesis.
The preventive trials initiated during ELASTAGE addressed the effect of Minoxidil or the
dill extracts on the consequence of elastic fibres disappearance in ageing (susceptibility to
aneurysms or varicose veins for instance). Those assays must be completed by continuing the
ongoing collaborations.
The pharmaceutical treatment of children harbouring inherited imperfect elastogenesis
has been an exciting issue emerging in the field. Two disorders have been studied during
ELASTAGE, cutis laxa and pseudoxanthoma elasticum. As those treatments are treating or
preventing the consequences of the diseases, and not the defective gene, they could be
extended to other syndromes. Therefore, the partners could share their experience with other
teams engaged in such actions on other related syndromes (Williams – Beuren, Marfan
syndromes for instance).
The link between aging and aging of elastic fibres has not really been answered by
ELASTAGE. In other words, it is yet unknown how elastic fibres are build up during
childhood and less (or even no more) later. Therefore, global mechanisms should be
considered, such as the ones occurring after growth (a role for growth hormone?), after
menopause (a role of oestrogens?) or after stress (a role of neurotrophins or oxidative
stress?). ELASTAGE has contributed by introducing new biomarkers and targets, such as
molecules involved in the epigenetic regulation of elastic fibres aging. These approaches and
questions would benefit of an integrated program addressing global questions upon ageing.
10
ELASTAGE – FP6 – Final Activity Report
Annexes
Work Packages table
WP1-A: Animal models: ageing versus elastic fibre ageing
WP1-B: Animal models: testing of selected compounds
WP2-A: Susceptibility assay of tropoelastin/fibrillin-1 to design protective peptido-mimetics.
WP2-B: Design, synthesis and evaluation of peptido-proteoglycan complexes
WP2-C: Improving the elastic properties of the tissue-engineering scaffolds.
WP2-D: Characterization of amyloidal elastic fibres to design peptide competitors
WP3-A: Search of the best activators of elastic fibre components (EFC) on aged A-vSMC in 2D.
WP3-B: Validation of EFC activator in 3D vessel-equivalent
WP3-C: Validation of EFC activator on the grafted tissue engineered blood.
WP4-A: Search of the best activators of EFC on aged A-HSF in 2D- culture.
WP4-B: Study for stimulating the regulation of elastin/fibrillin-1/LOXL).
WP4-C: Study for stimulating the mechanisms governed by EBP.
WP4-D: Validation of EFC activator in 3D skin-equivalent
WP5-A: Scaling up of the skin-equivalent model
WP5-B: development of the ageing and elastic fibre tissue ageing dedicated DNA array
WP5-C: validation on the "exaggerated elastic fibre ageing models (PXE, cutis laxa, VIC)
WP6: Exploitation and dissemination of knowledge
WP7: Management
Participants
Partic.
Role*
Parti
c. no.
Participant name
Participant short name
CO
1
Centre National de la Recherche Scientifique
UMR5086 - Institute of Biology and Chemistry,
University Lyon,
CNRS – Lyon
UMR 6237 CNRS Extracellular matrix and
Cellular Dynamics, University Reims
CNRS - Reims
Country
France
CR
2
University of Modena
UNIMORE - Modena
Italy
CR
3
University of Alcala de Henarès
UAH - Madrid
Spain
CR
4
University della Basilicata
UNIBAS - Potenza
Italy
CR
5
Manchester University
UNIMAN - Manchester
United Kingdom
CR
6
Initially Friedrich Schiller University, then Charité
Hospital Berlin, presently University Tubingen
Partner 6
Germany
CR
7
Initially COLETICA, then Engelhard – Lyon,
presently BASF-Beauty Care Solution
Partner 7
France
CR
8
OPOCRIN
OPOCRIN
Italy
CR
9
University of Pleven
MU - Pleven
Bulgaria
CR
10
Institut National de la Recherche Médicale U698
“cardiovascular remodelling, bioingeniering and
haemostasis'
INSERM – Paris
France
INSERM EMI 02.19 University Grenoble
INSERM - Grenoble
CR
11
Giannina Gaslini Hospital
IGG
Italy
CR
12
PROGENIKA Biopharma
PROGENIKA
Spain
11
ELASTAGE – FP6 – Final Activity Report
Deliverable
No
WP
D1.1
1
D1.2
1
D2.1
2
D2.2
2
D2.3
2
D2.4
2
D2.5
2
D3.1
3
D3.2
3
D3.3
3
D3.4
3
D4.1
4
D4.2
4
D4.3
4
D5.1
5
D5.2
5
D5.3
5
D5.4
5
D5.5
5
D6.1
6
D6.2
D7.1
D7.2
D7.3
D7.4
Deliverable title
Immunohistological and ultra-structural comparison of elastic fibres
tissues (skin/vessels) from Senescence Accelerated Mice (SAM),
"aged" and Eln +/- heterozygous mice in two different moments of
life (and females versus males): determination of suitable models to
study positive modulators of elastic fibre function
Immuno/histological, physiological, ultrastructural comparison of
elastic fibre tissues (skin/vessels) from "aged" Eln +/- heterozygous
mice and/or SAM mice treated with potential positive modulators of
elastic fibre function
Molecular and supramolecular characterization of elastin related
amyloidal fibres
Identification of the role played by different HS in degradation of
elastin
Studies on the interaction of tropoelastin, Fibrillin-1 and elastin
related domains with different HS prototypes from a molecular and
supramolecular point of view
Design and synthesis of peptido-HS conjugates and evaluation of
their activity as degradation preventing agent
Synthesis and characterization of biopolymers obtained by
chemically cross-linking linear elastin-like polypeptide sequences
Selection of the best activators of EFC on ELN+/- mice and aged
human vascular smooth muscle cells (A-vSMC) grown in twodimension culture, among a list of potential activators: Study of the
potassium channel regulation by the selected compound(s)
Report on protecting the EFC by adding anti-oxidant, anti-AGE and
peptide mimics and proteoglycans
Validation of the effectiveness of compounds on the sheep vSMC
used for the vessel equivalent months
In vivo evaluation on the engineered graft
Selection of the best activator/s of elastin renewal/protection on aged
human skin fibroblasts (A-HSF) grown in two-dimension culture,
among a list of potential activators
Determination of the modulation effect at Elastin-laminin receptor
level, at signalling pathways level and at elastin/LOXL promoters
Report on Eliciting the formation of EF in the skin equivalent by
using the selected compounds
Definition of the list of genes to be used for the dedicated DNA array
month
Standardisation, automation, and validation of 3D-cells models
Study of cells from skin and veins of VIC (as human models of
elastic tissue fragility
Screening on new substances to find the most effective ones that are
able to reverse targeted gene expressions
Test the efficiency of selected compounds using PXE fibroblasts,
Cutis laxa fibroblasts and VIC fibroblasts
Presentation of the Initial plan for the use and dissemination of
knowledge
Delivery
date
Status
M+18
Not finished
M+36
done
M+12
done
M+18
done
M+24
done
M+30
done
M+36
done
M+18
done
M+24
done
M+24
M+36
Cancelled and
replaced
Cancelled and
replaced
M+18
done
M+24
done
M+36
done
M+6
done
M+18
done
M+18
done
M+36
done
M+36
done
M+12
done
6
Final plan for the use and dissemination of knowledge
M+36
done
7
Kick-off general meeting
M+1
done
7
Mid-term assessment report
M+18
done
7
Ethical Council report
M+36
done
7
Mid-term assessment report
M+36
done
12
ELASTAGE – FP6 – Final Activity Report
Plan for using and disseminating the knowledge
1-Exploitation of knowledge
It will only contain exploitable results: knowledge with potential for industrial or commercial application
Exploitable
knowledge
Exploitable
product /
process /
service
Antiamyloidogenic
drugs
Elastininspired
biomaterials
Sector of
applicati
on
Exploitation
timetable
IPR
protection
(patents)
Other
partners
involved
Owner
Biomedicine
UNIBAS
Biomedicine
UNIBAS
PARNAPARIN
FRACTIONS
Products
AND process
Biomedicine
***
SUBSTANCE
FOR
RESTORING
NORMAL COEXPRESSION
AND
INTERACTION
BETWEEN LOX
AND NRAGE
PROTEINS
Products
Cosmetic
and
dermatolo
gy
Patent filed
on
05/10/2007
MI2007A0011926
OPOCRIN
Publication
number:
KR2008010033
3 (A)
Publication
date:2008-11-07
Application
number:
KR2008701265
7 20080527
Priority number;
FR20050011112
20051028
* OPOCRIN Patent “Multimicrolamellar collagen membranes” Inventors: B. Parma, A.
Gigante. Obtained on 18/10/2007. during Elastage study the membrane was furtherly studied
enriched with natural and semi-synthetic heparan sulphates
**OPOCRIN patent (“Heparin fractions having new biological activities, obtained with an
integrated depolimerization process, and the process for their preparation” - Inventors: L. Liverani, G.
Mascellari, B. Parma, P. Bianchini) was filed on 05 October 2007 : it claims the low molecular weight
fractions developed during the ELASTAGE study and coded for the partners as: OP-E 110, 111, 112,
113, 114, 115 and OP-E 117, 118, 120, 121.
***BASF BCS: patent extended worldwide in 2008 with the addition of new active
compounds screened and selected during Elastage .
13
ELASTAGE – FP6 – Final Activity Report
2-Dissemination of knowledge (press, media, conference, exhibition…)
Dissemination
date
1- 2006
2-June 2006
3- June 2006
4- July
5- From summer
2006
6- From summer
2006
7- From summer
2006
Dissemination
type
Publication
Newspaper article
Newspaper article
Newspaper article
Web article
Web article
Web article
8- 2-4 July 2006
poster
9- 9-12 July, 2006
Congress
poster
10- 9-12 July 2006
poster
11- 9-12 July 2006
conference
12- 9-12 July 2006
13- 9th-14th July
2006
14- 9th July 2006.
15- 9th July 2006.
Poster
Conference
Conference
16- 9th July 2006
Conference
17- 9th July 2006
Poster
18- 9th July 2006
Poster
19 - 9th July 2006
conference
20 - 9th July 2006
Conference,
Audience type
Audience
location
Audience size
Scientific
community
General public
UNIBAS
Italy
Academic
Community
General Public
General Public
General Public
General Public
International
Scientific
Community
Scientific
community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
scientific
community
International
Scientific
Community
International
14
Partner
involved
People living in
Modena and in
surrounding region
All people
working in the
University in
Modena and in
Reggio Emilia
People living in
Modena and in
surrounding region
UNIMORE
UNIMORE
WEB Community
UNIMORE
WEB Community
UNIMORE
WEB Community
UNIMORE
Pisa, Italy
Lyon, France
UNIMORE
UNIMORE
120 persons
all
120 persons
Lyon, France
UNIMORE
120 persons
Lyon, France
UNIMORE
120 persons
Lyon, France
UNIMORE
Lyon, France
120 persons
UNIBAS
Lyon, France
120 persons
UNIBAS
Lyon, France
120 persons
UNIBAS
Lyon, France
120 persons
CNRS-Reims
Lyon, France
120 persons
CNRS-Reims
Lyon, France
120 persons
INSERMGrenoble
Lyon, France
120 persons
Engelhard
Lyon, France
120 persons
Engelhard
ELASTAGE – FP6 – Final Activity Report
poster
21- August 2006
publication
22- September
2006
23- September
2006
Newspaper article
Web site
advertisement
24- 7-9 September
2006
Poster
25- 19-22
September 2006
26- October 2006
2006
web site
advertisement
General public
Conference
European scientific
community
Conference
29- 4th-7th October
2006
International
scientific
community
International
scientific
community
National scientific
community
28- 4th-7th October
Conference
European
Scientific
community
European
Scientific
community
30- 26-27 October
2006
Oral
communication on
a meeting with
abstracts
published on an
International
Journal
International
Scientific
Community
31- 8 et 9 Février
2007
Presentation
French Scientific
community
32- 26-27 October
2006
33- 26-27 October
2006
Oral
communication on
a meeting with
abstracts
published on an
International
Journal
Oral
communication on
a meeting with
abstracts
published on an
International
Journal
UNIBAS
French scientific
community
Poster
27- 4-7 October
2006
Scientific
Community
International
scientific
community
CNRS-Lyon
CNRS-Lyon
Paris, France
Engelhard
Pavia, Italie
UNIMORE
All
Bordeaux,
France
INSERMGrenoble,
UNIMAN
Bordeaux,
France
UNIBAS
Bordeaux,
France
INSERM/UNI
MAN
Padova (Italy)
UNIMORE
INSERM
International
Scientific
Community
Padova (Italy)
UNIMORE,
OPOCRIN
International
Scientific
Community
Padova (Italy)
UNIMORE
34 - October 2006
Publication
International
Scientific
Community
UNIBAS
35- November 2006
Publication
International
Scientific
Community
UAH, CNRSLyon
15
ELASTAGE – FP6 – Final Activity Report
36- November 2006
Publication
37- 2006/2007
Publication
38- 2007
Publication
39- 2006/2007
Publication
40- 2006/2007
Publication
41- 2006
Publication
42- 2006
Publication
43- 2006
Publication
44- 19 mai 2007
Presentation
45- January 2007
Publication
46-February 2007
Paper submitted
47- 2007
Publication
48- 2007
Publication
Publication
49- 2007
50- 2007
51- 23 March 2007
Publication
Conference,
Poster
Publication
52- 2007
Publication
53- June 2007
Publication
54- June 2007
55- June 14-16,
2007
poster
56- 17-21 June
2007
poster
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
scientific
community
International
scientific
community
International
scientific
community
French Scientific
community
Scientific
community
Scientific
community
International
Scientific
Community
International
Scientific
Community
International
scientific
community
International
scientific
community
National scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
National scientific
community
National scientific
community
16
UAH
UNIMORE /
CNRS Lyon
BASF
BCS/CNRS
Biogerontology
UNIMORE
UNIMORE
UNIMAN
UNIMAN
UNIMAN
INSERM
UNIBAS
IGG
CNRS-Lyon;
Engelhard
UNIBAS
UNIMAN
UNIMAN
Caen, (France)
100 persons
CNRS-Reims
UNIBAS
UNIBAS
UNIBAS
Biarritz, France
(nSFA congress)
Prague
(Czech
Republic)
200 persons
INSERM-Paris
UNIMORE
ELASTAGE – FP6 – Final Activity Report
57-17-21 June 2007
58- 26-29 June
2007
59- 26-29 June
2007
poster
Oral presentation
Oral presentation
60- 2007
Publication
61- 2007
Publication
62- 29th July 2007.
Conference
Poster
63-2007
Poster
64- September
2007
Oral presentation
65- 26-29
septembre 2007
presentation
66- 25-28
September 2007
Meeting Invited
Lecture
67--2007
Oral Presentation
68--2007
Poster
69-2007
Poster
70--2007
Oral Presentation
71--2007
Poster
72- September
2007
Oral Presentation
73 -2007/2008
Publication
74- 12th March
2008.
Conference
Poster
75- 5-9 April 2008
Poster and
abstract
publication
76- 2008
Publication
National scientific
community
National Scientific
Community
National Scientific
Community
International
scientific
community
International
scientific
community
International
Scientific
Community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
Scientific
Community
International
Scientific
Community
International
scientific
community
17
Prague
(Czech
Republic)
AcitrezzaCatania (Italy)
AcitrezzaCatania (Italy)
UNIMORE
UNIMORE
UNIMORE
UNIBAS
UNIBAS
Biddeford, USA
150 persons
EKUT
Biddeford, ME
(Maine), USA.
UNIBAS
Barcelona
(Spain)
UAH
Barcelona
(Spain)
INSERM
Belgrade
(Serbia)
UNIMORE
BarcellonaSpain
UNIBAS
BarcellonaSpain
UNIBAS
BarcellonaSpain
UNIBAS
Groningen-(The
Netherland)
UNIBAS
Groningen-(The
Netherland)
UNIBAS
Cordoba (Spain)
UAH,
INSERMGrenoble
UNIMORE
INSERM
Hilton Head,
USA
San Diego
(USA)
150 persons
EKUT
UNIMORE
UNIBAS
ELASTAGE – FP6 – Final Activity Report
77 – May 2008
Poster
78- 2008
Publication
79- 2008
Presentation
80- July 2008
publication
81- 9-13th July 2008
Poster
82- 2008
Lecture
83 – July 2008
Poster
84- 2008
Lecture
85- July 2008
Presentation
86- July 2008
Presentation
87- July 2008
Poster
88- July 2008
89- July 2008
Poster
Lecture
90-2008
Opening Lecture
91-2008
Lecture
92- 2008
Oral Presentation
93-2008
Poster
94-2008
Poster
95- July 2008
Poster
96- July 1619,2008
Poster
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
5th Elastin
European Meeting
18
Kyoto, Japan
>1000
BASF BCS
UNIBAS
Selva di Fasano,
Italy
UNIMORE
CNRS-Lyon
Marseillle,
France
300
BASFBCS/CN
RS Lyon
Marseille
(France)
300
UNIBAS
Marseille
(France)
300
CNRS-Reims
Marseille
(France)
300
UNIBAS
Madrid (Spain)
CNRS
Madrid (Spain)
CNRS
Madrid (Spain)
120
UNIMORE
120
UNIMORE/OP
OCRIN
120
UNIMORE
Madrid (Spain)
120
UNIBAS
Madrid (Spain)
120
UNIBAS
Madrid (Spain)
120
UNIBAS
Madrid (Spain)
120
UNIBAS
Madrid (Spain)
120
UNIBAS
Alcalá de
Henares (Spain)
120
Madrid, Spain
120
Madrid (Spain)
Madrid (Spain)
UAH,
INSERMGrenoble
UH - Pleven
ELASTAGE – FP6 – Final Activity Report
97- July 16-19,2008
Oral
communication on
a meeting with
abstracts
published
98- 16th July 2008.
Conference
Poster
100- July 2008
Poster
101- July 2008
Poster
102- July 2008
Poster
102July 2008
103- July 2008
Poster
Poster
104- July 2008
Poster
105- July 2008
Poster
106-16-20 August
2008
Poster
107-16-20 August
2008
Poster
108- 30 august- 3
September 2008
Oral
communication on
a meeting with
abstracts
published in
European Heart
Journal
Meeting with
abstracts
published on an
International
Journal
Invited Lecture
109- 10-13
September 2008
5th Elastin
European Meeting
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
5th Balkan
Congress of
Immunology
5th Balkan
Congress of
Immunology
International
scientific
community
International
scientific
community
World Congress of
Cardiology
120
UH - Pleven
Alcalá de
Henares, Spain
120 persons
Madrid
120
IGG
Madrid
120
IGG
Madrid
120
Madrid
120
Madrid
120
Ohrid,
Macedonia
200
UH - Pleven
Ohrid,
Macedonia
200
UH - Pleven
EKUT
INSERM
INSERM
INSERM
Amsterdam
(Nederland)
UNIMORE
Amsterdam
(Nederland)
UNIMORE
Munich
Germany
2000
UH – Pleven,
Cosenza
UNIMORE
Oral presentation
International
scientific
community and
cosmetic
companies
New-York City,
USA
BASF BCS
111- September
2008
Oral presentation
International
scientific
community
Villa Vigoni
(German-Italian
cultural Center)
Menaggio - Italy
OPOCRIN
112- 2008
Publication
International
scientific
community
110- September
2008
International
scientific
community
Madrid, Spain
19
UAH/INSERM
ELASTAGE – FP6 – Final Activity Report
113- 2008
Publication
114- 2008
Publication
115- 2008
Lecture
116- 2008
Oral Presentation
117- 2008
Oral Presentation
118- 2008
Oral Presentation
119 oct 2008
Publication
120 oct 2008
Poster
121- 6-9 october
2008
Oral presentation
122
- 6-7 November
2008
123- 6-7 November
2008
124- 6-7 November
2008
Meeting with
international
publication
Meeting with
international
publication
Meeting with
international
publication
125- 26 November
2008
Presentation
126- 2008
Publication
127- 70- November
2008
Oral presentation
128- 2008
Publication
129- 2008
Publication
130-2008
Publication
131- 2009 (end
2008)
Publication
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
community and
cosmetic
companies
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
Scientific
Community
International
scientific
community and
cosmetic
companies
International
scientific
community
International
scientific
community
International
scientific
community
International
scientific
20
UNIBAS
UNIBAS/UNI
MORE
Reims (France)
UNIBAS
Reims (France)
UNIBAS
Reims (France)
UNIBAS
Reims (France)
INSERM
INSERM-P,
CNRS-L
Anthalya
(Turkey)
500
UH – Pleven,
Barcelona,
Spain
BAF BCS
Pavia (Italy
UNIMORE
Pavia (Italy
UNIMORE
Pavia (Italy
UNIMORE
Paris (France
INSERM
ALL
Telford, UK
BASF BCS
UNIBAS
UNIMAN
CNRS
Skin Res.
Techno.
BASF BCS
/CNRS
ELASTAGE – FP6 – Final Activity Report
community
132- 2008
Publication
133- 2008
Chapter in Book
International
scientific
community
International
scientific
community
UNIBAS
UNIMORE
More details [relevant detail (e.g. journal references, conferences, website addresses), completed an future
activities]
1-.Transformation of Amyloid-like Fibers, Formed from an Elastin-Based Biopolymer, into a
Hydrogel: An X-ray Photoelectron Spectroscopy and Atomic Force Microscopy. R. FLAMIA, A. M.
SALVI, L. D’ALESSIO, J. E. CASTLE A.M. TAMBURRO
Biomacromolecules (2006)
2- Elastage, stop all’invecchiamento dei tessuti. Gazzetta di Modena, 11 June 2006
3- Elastage: una terza età più in forma. Giornale dell’Università di Modena e Reggio Emilia, n. IV June 2006
4- Più giovani con l’Università. Ricerche sulle fibre elastiche grazie alla Prof. Daniela Quaglin
Gazzetta di Modena, 23 July 2006
5- Unimore: una sfida chiamata Elastage. www.controcampus.it/news/mostrabollettino.asp?id=7857
6- Invecchiamento della fibra elastica, la UE sponsor del progetto ELASTAGE
http://it.health.yahoo.net/p_news.asp?id=15897&c=44&s=14
7- Elastage, il progetto universitario che sfida l’invecchiamento dei tessuti del corpo umano
www.ricercaitaliana.it/news/news_ente-static_26.htm
8- The synergic effect of oxidative stress and hypoxia on the proteome of cultured dermal fibroblasts.
Boraldi F., Annovi G., Carraio F., Naldini A., Becchi M., Paolinelli Devincenzi C., Tiozzo R.,
Pasquali-Ronchetti I., Quaglino D.
Proceeding ItPA , Pisa 2-4 July 2006
9- The 4th European meeting on Elastin was organized by Pascal Sommer. All the partners participated
to this meeting which takes place every two years in alternation with the Gordon conference on Elastin
(USA). The Elastage's participants are well involved in this congress as the second one was organized
by Antonio Tamburro (UNIBAS), the third one was organized by Catherine Kielty (UNIMAN) and the
next one (July 2008) will be organized by Julia Bujan (UAH). This meeting gets together best scientist
of the world on Elastin. (web site : http://web.ujfgrenoble.fr/BIO/elastin2006/)
10- The synergistic effect of stress conditions on the protein profile of human dermal fibroblasts.
Boraldi F., Annovi G., Becchi M., Paolinelli Devincenzi C., Guidetti R., Gheduzzi D., Carraro F.,
Tiozzo R., Pasquali-Ronchetti I., Quaglino D. 4th European Meeting on Elastin, Lyon 9-12 July, 2006
11- Heparan sulphate is specificallyu associated with detective elastic fibers in fibulin 4 -/- mice.
Gheduzzi D., Guidetti R., MCLaughlin PJ., Marmorstein L., Pasquali Ronchetti I., Quaglino D.
4th European Meeting on Elastin, Lyon 9-12 July, 2006
12- Genetioc and epigenetic factors in elastic fiber calcification in PXE. Pasquali-Ronchetti
4th European Meeting on Elastin, Lyon 9-12 July, 2006
13- Synthesis of and structural studies on repeating sequences of resilin. Panariello S., Giordano M.,
Bochicchio B., Tamburro AM. 4th European Meeting on Elastin, Lyon 9-12 July, 2006
14- Assembling the molecular elastin puzzle(OP). A. M. Tamburro. 4th European Meeting on Elastin,
Lyon 9-12 July, 2006
15- Assembling the supramolecular elastin puzzle(OP). B. Bochicchio, A. Pepe, A. M. Tamburro.
4th European Meeting on Elastin, Lyon 9-12 July, 2006
21
ELASTAGE – FP6 – Final Activity Report
16-Elastin peptides promote cell survival of human skin fibroblasts. Debelle L.
17- Elastin peptides promote cell survival by counterbalancing ceramide-induced apopotosis.
Cantarelli B., Duca L., Blanchevoye C. Delacoux F., Martiny L. et Debelle L. 4th European Meeting on
Elastin, Lyon 9-12 July, 2006
18- Role of fibrillin-1 in vascular function during aging. Study in Fbn1+/mgA mice. B Mariko, M
Quentin, M Coquand-Gandit, F Ramirez and G Faury.
4th European Meeting on Elastin. July 9-12, 2006, Lyon, FRANCE.
19- Gene expression modulators for elastic fiber maintenance and repair. V. Andre, V. Cenizo, O.
Damour, P. Sommer 4th European Meeting on Elastin, Lyon 9-12 July, 2006
20- The Lysyl Oxidase-Like 1 : A New Potential Target to Induce the Elastic Fibers Formation. V.
Cenizo, V. André, C. Reymermier, I. Orly, O. Damour, P. Sommer 4th European Meeting on Elastin,
Lyon 9-12 July, 2006
21- Localizing α-helices in human tropoelastin: assembly of the elastin puzzle. A. M. Tamburro, A.
Pepe, B. Bochicchio Biochemistry, 45:9518-9530 (2006).
22- Press article in the national journal ARTEB (Agence Rhône-Alpes pour le développement des
Technologies Médicales et des Biotechnologies) N°43. Elastage ; le vieillissement des tissus élastiques,
les nouveaux défis en santé humaine. http://www.arteb.com/
23- Advertisement on the web site Institut de Biologie et de Chimie des protéines :
http://www.ibcp.fr/fr/index.php?page=projets.html
24- Two selected active ingredients improve skin elasticity by increasing the Lysyl oxidase-Like
expression. V. Cenizo, V. André, C. Reymermier, I. Orly, A. Elsheikh, O. Damour et P. Sommer.
EDSR, Paris, 7-9 September, 2006 JID volume 126 supplement 3 auguste 2006page S26 (poster n°142)
25- Microanalisi a raggi X su sezioni di fibre elastiche del derma umano in funzione dell’età. Guerra
D., Zapparoli M., Pasquali-Ronchetti I., Quaglino D. Proceedings XXVIII SIP Meeting, p. 45 poster
26- Advertisement on the web site ERA-AGE (ERA-NET, FP6) :
http://eraage.group.shef.ac.uk/links.php
27- Role of fibrillin-1 in Vascular cell function, structure and mechanics. B Mariko, M Quentin, M
Coquand-Gandit, D Bax, F Ramirez, C Kielty and G Faury. XXII Latin meeting on vascular research,
Bordeaux-France 4th-7th October 2006 http://u441.hleveque.bordeaux.inserm.fr/liac
28- Elastin amyloids: are they revelant to cardiovascular system? B. Bochicchio, A. Pepe, A.Ostuni,
F.Bisaccia, A. M. Tamburro XXII Latin meeting on vascular research, Bordeaux-France 4th-7th October
2006 http://u441.hleveque.bordeaux.inserm.fr/liac
29- Mariko B, Quentin M, Coquand-Gandit M, Bax D, Ramirez F , Kielty C and Faury G. Role of
fibrillin-1 in Vascular cell function, structure and mechanics. 22nd Latin Meeting on Vascular
Research (LIAC). 4-7 octobre 2006. Bordeaux, France
30- Is Matrix Gla Protein (MGP) a key regulator of elastic fiber calcification? Annovi G., Gheduzzi
D., Boraldi F., Schurgers LJ., Tiozzo R., Quaglino D., Pasquali-Ronchetti I. Proceedings XXVI SISC
Meeting, Padova 26-27 October, 2006Proceedings XXVI SISC Meeting, Connect. Tissue Res, 48: 112113, 2007
31- Faury G. Exploration fonctionnelle du système cardiovasculaire de souris invalidées pour le
gène
de
l’élastine
(Eln+/- et Eln-/-). Journées Développement de l’Enfant et Génétique. Université de Poitiers. 8 et 9
Février 2007. Poitiers, France.
32- Tropoelastin deposition in cultured human dermal fibroblasts is affected by addition of heparin
sulphate. Guidetti R., Croce MA., Gheduzzi D., Parma B., Pasquali-Ronchetti I., Tiozzo R., Quaglino
D. Proceedings XXVI SISC Meeting, Padova 26-27 October, 2006, Connect. Tissue Res, 48: 113, 2007
33-Is Matrix Gla Protein (MGP) a key regulator of elastic fiber calcification? Annovi G., Gheduzzi D.,
22
ELASTAGE – FP6 – Final Activity Report
Boraldi F., Schurgers LJ., Tiozzo R., Quaglino D., Pasquali-Ronchetti I. Proceedings XXVI SISC
Meeting, Padova 26-27 October, 2006, Connect. Tissue Res, 48: 116-117, 2007
34- Molecular and supramolecular structural studies on human tropoelastin sequences. Angela Ostuni,
Brigida Bochicchio, Maria F. Armentano, Faustino Bisaccia and Antonio M. Tamburro Biophys. J.,
2007, 93(10), 3640-50
35-Down-regulation of lysyl oxydase-like in aging and venous insufficiency. Pascual G, Mendieta C,
Mecham RP, Sommer P, Bellón JM, Buján JHistol Histopathol. 2008 Feb;23(2):179-86..
36- TGF-beta 1 up-regulation in the aging varicose vein. G. Pascual, C. Mendieta, N. GarcíaHonduvilla, C. Corrales, J. M. Bellón, J. Buján Journal of Vascular Research, 2007; 44:192-201.
37- Hypoxia influences the cellular cross-talk of human dermal fibroblasts. A proteomic approach.
Boraldi F., Annovi G., Carraio F., Naldini A., Tiozzo R., Sommer P, Quaglino D. Biochim Biophys
Acta (Proteins & Proteomics). 1774:1402-13, 2007
38- Supplementation with a complex of active nutrients improved dermal and epidermal characteristics
in skin equivalents generated from fibroblasts from young or aged donors. Lacroix S, Bouez C, Vidal S,
Cenizo V, Reymermier C, Justin V, Vicanová J, Damour O. Biogerontology. 2007 Apr;8(2):97-109.
Epub 2006 Sep 23
39- The effect of serum withdrawal on the protein profile of quiescent human dermal fibroblasts in
primary cell culture Boraldi F., Annovi G., Paolinelli Devincenzi C., Tiozzo R., Quaglino D.
Proteomics. 8:66-82, 2008
40 Matrix Gla Protein (MGP) is involved in elastic fiber calcification in the dermis of
Pseudoxanthoma Elasticum patients. Gheduzzi D., Boraldi F., Annovi G., DeVincenzi C., Schurgers
L., Vermeer C., Quaglino D., Pasquali Ronchetti I. Laboratory Investigation, 87:998-1008, 2007
41- Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but
does not support receptor activation. Lomas AC, Mellody KT, Freeman LJ, Bax DV, Shuttleworth CA,
Kielty CM (2007) Biochem. J. 405, 417-428.
42- The role of endothelial cell attachment to elastic fibre molecules in the enhancement of monolayer
formation and retention, and the inhibition of smooth muscle cell recruitment. Williamson MR,
Shuttleworth A, Canfield AE, Black RA, Kielty CM (2008) Biomaterials 28, 5307-5318.
43- Cell adhesion to fibrillin-1: identification of an Arg-Gly-Asp-dependent synergy region and a
heparin-binding site that regulates focal adhesion formation. Bax DV, Mahalingam Y, Cain S, Mellody
K, Freeman L, Younger K, Shuttleworth CA, Humphries MJ, Couchman JR, Kielty CM (2007) J. Cell
Sci. 120, 1383-1392.
44- Faury G. Un modèle animal de malformations cardiovasculaires présentes dans le syndrome
de Williams-Beuren. 3ème colloque national de l’association Williams-France. 19 mai 2007. SaintEtienne, France.
45- Transformation of Amyloid-like Fibers, Formed from an Elastin-Based Biopolymer, into a
Hydrogel: An X-ray Photoelectron Spectroscopy and Atomic Force Microscopy. R. FLAMIA, A. M.
SALVI, L. D’ALESSIO, J. E. CASTLE A.M. TAMBURRO Biomacromolecules, 8: 128-38 (2007)
46- Regulation of elastin promoter by lysyl oxidase and growth factors : cross control of lysyl oxidase
on TGF-1 effects. R. Oleggini, N. Gastaldo, A. Di Donato Matrix Biology, 2007 Jul;26(6):494-505.
Epub 2007 Feb 27
47- p.C217R mutation in fibulin-5 from cutis laxa patients is associated with incomplete extracellular
matrix formation in a skin equivalent model. Claus S, Fischer J, Mégarbané H, Mégarbané A, Jobard F,
Debret R, Peyrol S, Saker S, Devillers M, Sommer P, Damour O. J Invest Dermatol. 2008
Jun;128(6):1442-50. Epub 2008 Jan 10
48-Supramolecular organization of elastin and elastin-related nanostructured biopolymers. B.
Bochicchio, A. Pepe, A. M. Tamburro Nanomedicine, 2007, 2, 203-218.
49- Heparan sulfate regulates fibrillin-1 N- and C-terminal interactions. Cain SA, Baldwin AK,
23
ELASTAGE – FP6 – Final Activity Report
Mahalingam Y, Raynal B, Jowitt TA, Shuttleworth CA, Couchman JR, Kielty CM (2008) J. Biol.
Chem. 283, 27017-27027.
50- Marfan syndrome-causing mutations in fibrillin-1 result in gross morphological alterations and
highlight the structural importance of the second hybrid domain. Mellody KT, Freeman LJ, Baldock C,
Jowitt TA, Siegler V, Raynal BD, Cain SA, Wess TJ, Shuttleworth CA, Kielty CM (2006) J. Biol.
Chem. 281, 31854-31862.
51- Elastin peptides promote cell survival by counterbalancing ceramide-induced apoptosis. B.
Cantarelli, L. Duca, C. Blanchevoye, F. Delacoux, L. Martiny and L. Debelle SFTC, Caen 23 March,
2007
52- Molecular properties of a representative glycine-rich sequence of elastin - BocVGGVGOEt: a
combined FTIR experimental and quantum chemical investigation.G. Lanza, A.M. Salvi, A.M.
Tamburro THEOCHEM, 812, 25-37 (2007)
53- Molecular and supramolecular structural studies on human tropoelastin Sequences. A. Ostuni, B.
Bochicchio,. M.F Armentano, F. Bisaccia and A. M. Tamburro.) Biophys J. 2007 Nov 15;93(10):3640-51.
Epub 2007 Aug 10..
54 Elastic fibers and amyloid deposition in vascular tissue. B. Bochicchio, A. Pepe, A. M. Tamburro
Future Neurology, 2007, 2, 523-536.
55- (nSFA congress)
56- Ion and structural changes in dermal elastic fibers with age. Guerra D., Giubertoni R., Zapparoli
M., Pasquali-Ronchetti I., Quaglino D. Proceedings 8 MCM, Prague 17-21 June 2007, p. 521-522
57- The role of Matrix Gla Protein (MGP) in ectopic calcification Gheduzzi D., Annovi G., Boraldi F.,
Schurgers L., Vermeer C, Pasquali-Ronchetti I., Quaglino D. Proceedings 8 MCM, Prague 17-21 June
2007, p. 523-524
58- The protein profile of confluent human dermal fibroblasts is modulated by serum withdrawal
Boraldi F., Annovi G., Paolinelli DeVincenzi C., Tiozzo R., Quaglino D. Proceedings ItPA 2nd
Annual National Conference, Acitrezza 26-29 June 2007, p.38
59- New insights in the pathogenesis of Pseudoxanthoma elasticum revealed by proteome analysis.
Boraldi F., Annovi G., Tiozzo R., Pasquali-Ronchetti I,, Quaglino D. Proceedings ItPA 2nd Annual
National Conference, Acitrezza 26-29 June 2007, p.159
60- Investigating the amyloidogenic nanostructured sequences of elastin: the sequence encoded by
exon 28 of Human Tropoelastin Gene. B. Bochicchio, A. Pepe, R. Flamia, M. Lorusso, A. M.
Tamburro. Biomacromolecules, 2007, 8, 3478-86.
61- Charge transport and intrinsic fluorescence in amyloid-like fibrils. L.L. Del Mercato, G. Maruccio,
A. Della Torre, F. Calabi, S. Sabella, A.M. Tamburro, R. Cingolani, R. Rinaldi, P.P. Pompa. Proc.
Natl. Acad. Sci. U.S.A., 104, 18019-24, (2007).
62-Poster July 29-August 3, 2007, University of New England Biddeford, ME (Maine), USA.
63- Elastic fibers and amyloid deposition in vascular tissue. Bochicchio B., Pepe A., Lorusso M.,
Tamburro AM Elastin & Elastic Fibers, July 29-August 3, 2007, University of New England
Biddeford, ME (Maine), USA.
64. Vascular modifications with ageing process in senescence accelerated mouse. Corrales C ,
Coquand M , Gómez-Gil V, Trejo C, Faury G and Buján J. LIAC 2007. 26-29 September, Barcelona
(Spain).
65- Mariko B, Quentin M, Raveaud S, Usson Y, Kielty C, Ramirez F and Faury G. Aortic
microfibrils and fibrillin-1 sequences induce calcium signalling and proliferation in human
endothelial cells. 23rd Latin Meeting on Vascular Research (LIAC). 26-29 septembre 2007. Barcelone,
Espagne
24
ELASTAGE – FP6 – Final Activity Report
66- Microscopy: a valuable tool for understanding matrix pathology Quaglino D. Proceedings 3rd
Sebian Congress for Microscopy, Belgrade 25-28 September 2007, p 39-42
67- Molecular and supramolecular structure of dissected Exon-30 coded domain of human tropoelastin.
Armenante MR., Pepe A., Bochicchio B., Tamburro AM. XXIII LATIN MEETING ON VASCULAR
RESEARCH, (Barcelona-Spain)26th-29th September (2007).
68. Conformational studies on significant sequences of Resilin. Panariello S., Pepe A., Giordano M.,
Bochicchio B., Tamburro AM XXIII LATIN MEETING ON VASCULAR RESEARCH, (BarcelonaSpain)26th-29th September (2007).
69- Amyloidogenic sequences of elastin: exon28 and exon30-coded polypeptide sequences.
Bochicchio B., Belloy N., Lorusso M., Dauchez M., Pepe A., Martiny L., Nakanishi K., Tamburro A.
M. XXIII LATIN MEETING ON VASCULAR RESEARCH, (Barcelona-Spain) 26th-29th September
(2007).
70- Investigating by CD the molecular mechanism of elasticity of elastomeric proteins. A.M.
Tamburro. The 11th International Conference on Circular Dichroism University of Groningen, The
Netherlands 2nd-6th september 2007.
71- Pepe A., Panariello S., Giordano M., Bochicchio B., Tamburro AM. Conformational studies on
significant sequences of Resilin. The 11th International Conference on Circular Dichroism University
of Groningen, The Netherlands 2nd-6th september 2007.
72. Skin modifications with aging process in senescence accelerated mouse. Bujan J, Corrales C,
Coquand M, Garcia Honduvilla N, Pascual G, Rodriguez M, Faury G. II Internacional congreso of
Histology and tissue engineering. 10-13 September, 2007. Cordoba (Spain).
73- -Elastin haploinsufficiency induces alternative aging processes in the aorta. Pezet M, Jacob MP,
Escoubet B, Gheduzzi D, Tillet E, Perret P, Huber P, Quaglino D, Vranckx R, Li DY, Starcher B,
Boyle WA, Mecham RP, Faury G. Rejuvenation Res.;11:97-112. 2008
74- Hilton Head, USA
75_ New insights into Pseudoxanthoma elasticum pathogenesis by proteome analysis. Quaglino D.,
Boraldi F., Annovi G., Guerra D., Panico F., Spaggiari A., DeSantis G., Tiozzo R., Ronchetti I.
Proceedings Experimental Biology 2008, San Diego 5-9 April 2008, FASEB J. 22:1121.13, 2008
76- Comment on the Mechanical Properties of the Amyloid Fibre, poly(ValGlyGlyLeuGly), Obtained
by a Novel AFM Methodology. R Flamia; P. Zdhan; J. E. Castle; A. M. Tamburro. J. Mat. Sci., 2008,
43, 395-397.
77 – Lysyl oxidase-like gene transcription is down-regulated in aged skin fibroblasts through a Sp-1rich promoter region. Valérie Cenizo, Romain Debret, Pascal Sommer, Valérie André. Poster. May
2008. International investigative Dermatology Conference Kyoto, Japan.
78- Amyloid-like fibrils in elastin-related polypeptides structural characterization and elastic
properties. L.L Del Mercato, G. Maruccio, P.P. Pompa, B. Bochicchio, A.M. Tamburro, R. Cingolani,
R. Rinaldi. Biomacromolecules, 2008, 9, 796-803.
79- Elastic fiber calcification: identification of pathogenetic pathways by proteome analysis. Annovi
G., Boraldi F., Tiozzo R., Ronchetti I., Quaglino D. Proceedings ItPA 3rd Annual National
Conference, Selva di Fasano, Italy 11-14 June 2008, p.38
80- Morpholino knockdown of lysyl oxidase impairs zebrafish development, and reflects some aspects
of copper metabolism disorders. Reynaud C, Baas D, Gleyzal C, Le Guellec D, Sommer P. Matrix Biol.
2008 Jul;27(6):547-60
81- Implication of Lysyl Oxidase in epidermal homeostasis. Gabrielle Le Provost, Valérie Cenizo,
Charbel Bouez, Valérie André and Pascal Sommer. FECTS Meeting ; Marseille, France 9-13th July
25
ELASTAGE – FP6 – Final Activity Report
2008.
82. Thermal Study Of Polypeptide Sequences From Human Tropoelastin By Differential Scanning
Calorimetry (DSC) Tintar, D., Samouillan, V., Dandurand, J., Lacabanne, C., Pepe A., Bochicchio B.,
Tamburro A. M.
XXIst Meeting Of The Federation Of The European Connctive Tissue Societies, Marseille, France, 9th13th, 2008
83- Effects of elastin peptides on ceramide-induced apoptosis. Cantarelli B., Duca L., Blanchevoye C.,
Delacoux F., Martiny L., Debelle L. XXIst Meeting of the Federation of European Connective Tissue
Societies, Marseille, France, 9 - 13 juillet 2008.
84- Structural Basis For The Formation Of Different Nanostructures By Self-Assembly Of Elastin
Peptides. Pepe, A., Armenante, M.R., Bochicchio, B., Tamburro, A.M. XXI Meeting Of The
Federation Of The European Connctive Tissue Societies, Marseille, France, July 9-13, 2008.
85- Morpholino knockdown of lysyl oxidase impairs zebrafish development, and reflects some aspects
of copper metabolism disorders. Reynaud C. . Proceedings Elastin2008, Alcalà de Henares 16-19 July
2008.
86- A Pharmalogical approach for Cutis Laxa. Sommer P. . Proceedings Elastin2008, Alcalà de
Henares 16-19 July 2008.
87- Pathways leading to impaired MGP carboxylation in fibroblasts from PXE patients. Boraldi F.,
Annovi G., Guerra D., Tiozzo R., Pasquali-Ronchetti I., Quaglino D. Proceedings Elastin2008, Alcalà
de Henares 16-19 July 2008.
88- Heparan sulfate influences elastic fiber formation:in vitro and in silico studies. Annovi G., Boraldi
F., Guerra D., Guidetti R., Croce A., Parma B., Tiozzo R., Pasquali-Ronchetti I., Quaglino D.
Proceedings Elastin2008, Alcalà de Henares 16-19 July 2008
89- On the pathogenesis of clinical manifestations in Pseudoxanthoma elasticum. Pasquali Ronchetti I.
Proceedings Elastin2008, Alcalà de Henares 16-19 July 2008
90- A never-ending love story with elastin : a scientific autobiography. Tamburro A.M. 5th ELASTIN
EUROPEAN MEETING ON ELASTIN, Alcalà de Henares, Madrid, Spain, July 16-19, 2008.
91- Supramolecular organizations of human tropoelastin domains (Lecture). Bochicchio B., Pepe A.,
Tamburro A. M. 5th ELASTIN EUROPEAN MEETING ON ELASTIN, Alcalà de Henares, Madrid,
Spain, July 16-19, 2008
92- On The Inhibition Of Elastin-Derived Amyloidogenesis. Bochicchio B., Lorusso, M., Tamburro
A. M. 5th ELASTIN EUROPEAN MEETING ON ELASTIN, Alcalà de Henares, Madrid, Spain, July
16-19, 2008.
93- Structural Studies On Significant Synthetic Sequences Of Resilin. Panariello S., Pepe A.,
Bochicchio B., Tamburro AM 5th ELASTIN EUROPEAN MEETING ON ELASTIN, Alcalà de
Henares, Madrid, Spain, July 16-19, 2008.
94- Characterization of proteolitic fragments of some domains of human tropoelastin by highperformance liquid chromatography with electrospray ionization mass spectrometry. A. Rubino, T.R.I.
Cataldi, A.M. Tamburro. 5th ELASTIN EUROPEAN MEETING ON ELASTIN, Alcalà de Henares,
Madrid, Spain, July 16-19, 2008. p.85
95. Inmunohistochemical expression of tropoelastin and fibulins 2, 3 and 4 in senescence-accelerated
mice skin. Romero B., Gª-Honduvilla N., Coquand-Gandit M., Faury G., Sasaki T., Mecham R.P.,
Bellón J.M., Buján J. 5th European Elastin Meeting. 16-19 July, 2008. Alcalá de Henares Madrid
(Spain).
96- M. Atanasova, A. Dimitrova, M. Georgieva, E. Konova, S. Baydanoff. Immunological aspects of
elastin turnover in senescence-prone and senescence-resistant mouse strains. 5th Elastin European
Meeting, Madrid, Spain, July 16-19,2008
26
ELASTAGE – FP6 – Final Activity Report
97- M. Atanasova, A. Dimitrova, M. Georgieva, E. Konova, S. Baydanoff. Quantity and capacity of
glycation of aortic elastin in SAMR1 and SAMP8:A study in two strains of senescence accelerated
mice. Oral presentation. 5th Elastin European Meeting, Madrid, Spain, July 16-19,2008
98- Elastin promoter regulation by TGF-b1 and lysyl oxidase Oleggini R., Gastaldo N., Di Donato A.
5th European Meeting on Elastin, 17-19 July 2008, Alcala de Henares, Madrid, (Spain)
99- 5th European Meeting on Elastin, 17-19 July 2008, Alcala de Henares, Madrid, (Spain)
100- LOX activation of MMTV promoter: mediated by histone H1 ? Oleggini R., Gastaldo N., Di
Donato A. 5th European Meeting on Elastin, 17-19 July 2008, Alcala de Henares, Madrid, (Spain)
101- M. Coquand-Gandit, M. Pezet, D. Y. Li and G. Faury. Minoxidil: a potential new treatment for
Williams Syndrome patients and prophylaxis of hypertension in elderly. 5th european elastin meeting.
16-19 juillet 2008. Alcala de Henares, Espagne.
102- Mariko B, Quentin M, Raveaud S, Usson Y, Jean Verdetti, Philippe Huber, Kielty C and Faury
G. Fibrillin-1-RGD-containing fragment PF14 induces integrin-mediated mobilization of intracellular
calcium stores, proliferation and migration of human endothelial cells. 5th european elastin meeting.
16-19 juillet 2008. Alcala de Henares, Espagne.
103 M. Atanasova, M. Georgieva, E. Konova, A. Dimitrova, S. Baydanoff. Age-related changes of
ant-elastin antibodies in ICR mice. 5th Balkan Congress of Immunology, July 2008г. Ohrid, Macedonia
104 M. Atanasova, M. Georgieva, E. Konova, A. Dimitrova, S. Baydanoff. Anti-AGE antibodies and
AGEs in ICR mice. 5th Balkan Congress of Immunology, July 2008г. Ohrid, Macedonia
105- T. Alexovska, E. Konova, M. Atanasova, M. Georgieva, Sv. Gecheva, G. Veleva, Tz. Lucanov.
Elastin turnover markers in patients with recurrent pregnancy loss. 5th Balkan Congress of Immunology,
July 2008г. Ohrid, Macedonia
106 New insights into the pathogenesis of ectopic calcificatios: a lesson from the PXE model. Annovi
G., Boraldi F., Schurgers LJ., Vermeer C., Pasquali Ronchetti I., Quaglino D. HUPO 7th Annual World
Congress, Amsterdam, 16 – 20 August 2008.
107- Characterization of the protein profile of fibroblasts from patients with Pseudoxanthoma
elasticum: from genetic to epigenetic pathogenesis. Boraldi F., Annovi G.,Guerra D., Tiozzo R.,
Pasquali-Ronchetti I., Quaglino D. HUPO 7th Annual World Congress, Amsterdam, 16 – 20 August
2008.
108- Stavreva G., V. Dancheva, V. Shopova, M. Atanasova, M. Georgieva, A. Dimitrova. S. Tisheva Changes of elastin turnover in Wistar-Kioto rats with amiodarone-induced pneumotoxicity - World
Congress of Cardiology -30 august- 3 September 2008 Munich European Heart Journal (2008) 29
(Abstract Supplement ), р.634. Impact factor 2007 = 1.619
109- A proteomic approach for investigating the aging process; the fibroblast model.
Quaglino D., Boraldi F., Annovi G.
Proceedings XXIX SIP Congress, Cosenza 10-13 September 2008. Am J. Pathol., 173S1: A02, 2008
110- Elastin Rejuvenation. S. Rogazik. Health and Beauty America (HBA) conference. NYC, USA,
September 2008
111- . Liverani, G. Mascellani: “Dermatansulphate as a minor component of heparins” ; 16th
Symposium on Glycosaminoglycans of Villa Vigoni, Sept. 2008 (oral presentation)http://www.villavigoni.it/
112- Skin modifications with aging process in senescence accelerated mouse. Bujan J, Corrales C,
Coquand M, Garcia Honduvilla N, Pascual G, Rodriguez M, Faury G. II Internacional congreso of
Histology and tissue engineering. 10-13 September, 2007. Cordoba (Spain).
113- Investigating by CD the molecular mechanism of elasticity of elastomeric proteins. B.
Bochicchio, A. Pepe, A. M. Tamburro. Chirality, 2008, 20, 985-94.
114- Exon 26-coded polypeptide: an isolated hydrophobic domain of human tropoelastin able to self27
ELASTAGE – FP6 – Final Activity Report
assemble in vitro. A. Pepe, R. Flamia, D. Guerra, D. Quaglino, B. Bochicchio, I. Pasquali Ronchetti, A.
M. Tamburro. Matrix Biol., (2008), 27, 441-450.
115- The self-assembly of elastin peptides: Molecular determinants for the formation of
nanostructures. A. Pepe. XXIV LIAC Meeting, Reims, France, 8-11th 2008. p. 10.
116- Elastin-derived amyloidogenesis inhibited by small molecules. M. Lorusso, B. Bochicchio, A.
Pepe, A. M. Tamburro. XXIV LIAC Meeting, Reims, France, 8-11th 2008. p. 13.
117. Characterization of the solvent onfluence on the structure of tropoelastin exon 6. D. Tindar, V.
Samouillan, J. Dandurand, C. Lacabanne, A. Pepe, B. Bochicchio, A. M. Tamburro. XXIV LIAC
Meeting, Reims, France, 8-11th 2008. p. 14.
118- M Coquand, JP Andrieu, B Starcher, S Bouillot , J Bujan and G Faury. Functional and
mechanical alterations of elastic arteries in the senescence-accelerated mouse (SAM-P8). XXIVth
LIAC meeting. 8-11 octobre 2008. Reims, France
119- Differential expression of lysyl oxidases LOXL1 and LOX during growth and aging suggests
specific roles in elastin and collagen fiber remodeling in rat aorta. Behmoaras J, Slove S, Seve S,
Vranckx R, Sommer P, Jacob MP. Rejuvenation Res. 2008 Oct;11(5):883-9
120- Aleksovska T., Konova E., Atanasova M., Georgieva M., Emin A., Lukanov Tz. Elastin turnover
in normal pregnancy and patients with history of recurrent pregnancy loss .2d Mediterranean Congress
of Clinical Immunology, October 2008, Anthalya, Turkey
121- Gene expression modulators for elastic fibers repair and maintenance. V. André, V. Cenizo, O.
Damour, P. Sommer. IFSCC, October 7th 2008. Barcelona, Spain. Oral communication
122- On the Pathogenesis of Elastic Fiber Calcification in Patients with Beta-Thalassemia and with
PXE-Like Clinical Manifestations Annovi G., Boraldi F., Tiozzo R., Guerra D., Cianciulli,P.,.
Sorrentino F., Forni G.L., Pasquali-Ronchetti I., Quaglino D. Proceedings XXVII SISC Meeting, Pavia
6-7 November 2008, Connective Tissue Res, in press
123- Proteomic Characterization of Cultured Aged Human Dermal Fibroblast Boraldi F., Annovi G.,
Tiozzo R., Quaglino D. Proceedings XXVII SISC Meeting, Pavia 6-7 November 2008, Connective
Tissue Res, in press
124- Does Lipid Metabolism Affect Clinical Manifestations in Pseudoxanthoma Elasticum? PasqualiRonchetti I, Gheduzzi D., Tarugi, P., Guerra D., Roggiani J., Boraldi F., Annovi G., Vanakker O.,
Couke P., De Paepe A.., Quaglino D. Proceedings XXVII SISC Meeting, Pavia 6-7 November 2008,
Connective Tissue Res, in press
125- G. Faury. Role of elastin and fibrillin-1 in cell signalling and structure-function relationship in
arteries 2nd Symposium on Cardiovascular Pathophysiology in Murine Models, 26 November 2008,
Paris, France.
126- Getting under the skin of tissue elasticity, p96-97, Issue November 2009, Estrategies Projects, by
british publishers
127- Lys’lastine, the elastin enablear. D. Bothorel. SCS Formulate. Telford (UK). November 2008
128- Formation of nanostructures by self-assembly of an elastin peptide. A. Pepe, M. R. Armenante,
B. Bochicchio, A. M. Tamburro. Soft Matter, 2008. DOI:10.1039/B811286J.
129- Kinsey R, Williamson MR, Chaudhry S, Mellody KT, McGovern A, Takahashi S, Shuttleworth
CA, Kielty CM (2008) Fibrillin-1 microfibril deposition is dependent on fibronectin assembly. J. Cell
Sci. 121, 2696-2704.
130- Genotype-correlated expression of lysyl oxidase-like 1 in ocular tissues of patients with
pseudoexfoliation syndrome/glaucoma and normal patients. Schlötzer-Schrehardt U, Pasutto F,
28
ELASTAGE – FP6 – Final Activity Report
Sommer P, Hornstra I, Kruse FE, Naumann GO, Reis A, Zenkel M. Am J Pathol. 2008 Dec;173(6):172435
131- Characterization of the mechanical properties of a dermal equivalent compared with human skin
in vivo by indentation and static friction tests.
Zahouani H, Pailler-Mattei C, Sohm B, Vargiolu R, Cenizo V, Debret R. Skin Res Technol. 2009
Feb;15(1):68-76
132- On enhancers and inhibitors of elastin-derived amyloidogenesis. B. Bochicchio, M. Lorusso , A.
Pepe, A. M. Tamburro. Nanomedicine, 2008, in press.
133- Elastin and elastin-based polymers. Quaglino D., Guerra D. Pasquali Ronchetti I. In “Nano and
biocomposites” Edited by Hussain F., Published by Taylor &Francis, in press
29
Download
Related flashcards

Histologists

23 cards

Staining

11 cards

Create Flashcards